Biosimilars for ophthalmologic indications are expected to save payers and the health system a great deal of money, based on the assumption that the comparator product (generally a reference product) is costly. However, this is not really the case. The most commonly used biologic for indications such as age-related wet macular degeneration or retinal vein … Continue reading Will MDs Use Bevacizumab Biosimilars to Treat Retinal Disorders? One Report Says Yes